Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Weixiong Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0009-7247-8111; OpenAlex author ID A5111624431. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 8

  1. Single-cell and spatial transcriptomics uncover a THBS2⁺ CAF-KRT17⁺ malignant cell axis drives progression and immunotherapy resistance in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2026.102939↗
  2. SLPI/FBW7/c-Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. Co-author DOI 10.1111/cas.70369↗
  3. Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications. First author DOI 10.1111/jgh.70441↗
  4. Tumor-associated neutrophils in pancreatic ductal adenocarcinoma: mechanisms and therapeutic targeting. First author DOI 10.3389/fimmu.2026.1806714↗
  5. Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. Co-author DOI 10.1111/cpr.70125↗
  6. MRI Detection of PDAC Response to KRAS Inhibitor Therapy—Letter Co-author DOI 10.1158/1078-0432.ccr-25-1546↗
  7. A risk signature based on endoplasmic reticulum stress-associated genes predicts prognosis and immunity in pancreatic cancer. Co-author DOI 10.3389/fmolb.2023.1298077↗
  8. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Co-author DOI 10.3390/biom12101450↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wence Zhou · 3 shared papers, 2022–2026 · strength 0.89
  2. Haofei Chen · 3 shared papers, 2023–2026 · strength 0.83
  3. Guoqing Zhang · 2 shared papers, 2026 · strength 0.70
  4. Xiaoyong Wu · 1 shared paper, 2026 · strength 0.43
  5. Liqin Ruan · 1 shared paper, 2026 · strength 0.43
  6. Run Shi · 1 shared paper, 2025 · strength 0.42
  7. Rui Ma · 1 shared paper, 2026 · strength 0.33
  8. Junhong Guan · 1 shared paper, 2026 · strength 0.33
  9. Shaohui Xu · 1 shared paper, 2025 · strength 0.22
  10. Zhaokai Zhou · 1 shared paper, 2025 · strength 0.22
  11. Yang Feng Wu · 1 shared paper, 2025 · strength 0.22
  12. Wenjie Shi · 1 shared paper, 2025 · strength 0.22
  13. Xin Li · 1 shared paper, 2022 · strength 0.19
  14. Wenkai Jiang · 1 shared paper, 2022 · strength 0.19
  15. Shi Dong · 1 shared paper, 2022 · strength 0.19
  16. Hao Xu · 1 shared paper, 2023 · strength 0.18
  17. Daoming Liang · 1 shared paper, 2023 · strength 0.18
  18. Wence Zhou · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.